Overview
Aptos (APT) and Injective (INJ) sit at different layers of the crypto stack. At current prices ($0.565000 vs $5.08), market leadership still favors Aptos on capitalization, while 24h tape is led by Injective.
Quick winners
Full comparison
| Metric | APT | INJ |
|---|---|---|
| Price | $0.565000 | $5.08 |
| Market Cap | $529.32M | $490.41M |
| FDV | — | — |
| Volume 24h | $2.38M | $2.27M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 101.00 | 99.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.39% | +5.97% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | APT | INJ |
|---|---|---|
| 1H | — | — |
| 24H | +2.35% | +4.65% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | APT | INJ |
|---|---|---|
| RSI | 34.62 | 49.29 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.03 | 0.29 |
| ADX | 28.06 | 12.19 |
| Support | — | 4.91 |
| Resistance | 0.64 | 5.47 |
| Trend | bearish | neutral |
| Momentum | — | — |
| Signal | neutral | neutral |
Automatic technical analysis
Relative technical health favors reading both charts side by side. AI scores (47.90 vs 47.50) summarize PEPS modules, but supports and resistances still decide invalidation.
Fundamentals
| Metric | APT | INJ |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | 0.00 |
| Github activity | 0.00 | 118.00 |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Aptos
Injective
Pros and cons
Pros of Aptos
- Market-cap scale on Aptos may dampen some idiosyncratic shocks versus smaller peers.
- Higher ranking for Aptos can translate into tighter spreads on major venues.
- Aptos typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
Cons of Aptos
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Indicator stacks on Aptos may stay stretched longer than expected in strong trends.
- Regulatory or macro headlines can hit Aptos harder simply because it is more visible.
Pros of Injective
- If technical momentum aligns, Injective may outperform on medium-term windows.
- PEPS tracking for Injective still includes AI score and level context for monitoring.
- Diversifying versus Aptos with Injective can change portfolio factor exposure.
- Injective can offer higher relative beta when market attention rotates toward its niche.
Cons of Injective
- Higher volatility on INJ cuts both ways and demands stricter risk limits.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
- Smaller book depth versus large caps can increase slippage for Injective.
- Relative underperformance versus Aptos can persist through entire market regimes.
Which looks stronger right now?
If you weight capitalization and liquidity, Aptos looks sturdier; if you weight 24h tape, Injective is ahead. A balanced view treats both as incomplete signals.
AI summary
For readers asking which is “better”, the honest answer is conditional. Aptos and Injective solve overlapping but not identical market jobs. On-chain and developer fields, when available, add slower-moving context beneath the tape. Missing fundamentals should be treated as unknown, not as zeros. If your thesis is long-term adoption, weight fundamentals and liquidity; if tactical, weight trend/momentum — and always define invalidation.
FAQ
Which is better, Aptos or Injective?
“Better” depends on horizon and risk. Aptos leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, APT or INJ?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Aptos and Injective.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Aptos currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.